Maven Bio GTM brain

category

market profile

• text: Drug, trial and market access evidence changes between periodic reviews, potentially making an asset screen or forecast stale.
• text: Specialist intelligence vendors combine drug pipeline data, analytics and monitoring for competitive intelligence and business development teams.

personas

• title: Biopharma competitive intelligence lead
  pains:

  • Competitor trial and regulatory changes make landscape decks stale between reviews
  • A small team cannot monitor every relevant asset, geography and source by hand
• title: Business development and portfolio strategy lead
  pains:

  • Screening therapeutic assets requires reconciling clinical, company and access evidence
  • New evidence can change differentiation assumptions before a deal decision
• title: Life sciences consulting or investment research lead
  pains:

  • Recurring client readouts and diligence files need constant refreshes
  • Analysts must inspect evidence and preserve their own research methods

icp

• text: Pharma and biotech organizations with dedicated medical affairs, business development, competitive intelligence, strategy, access or forecasting teams.
• text: Life sciences consultancies and investment firms producing recurring therapeutic opportunity screens and diligence assessments; firm size is not specified.

message pillars

• text: Replace point-in-time research with continuously refreshed intelligence.
• text: Assess new evidence against the team's actual decisions.
• text: Keep project files inspectable and reversible as evidence changes.

objections

• objection: Can AI edits be trusted in high-stakes research?
  response: Review linked evidence and revisions, and use rollback and human judgment before relying on an updated assessment.
• objection: Will it fit our existing research methods?
  response: Pilot a real asset screen and working document, then evaluate file downloads, assistant connections and API access.
• objection: How does pricing scale with our team?
  response: Request a custom quote covering data rights, team access, monitors and pooled AI usage.

competitors

• name: Citeline
  website: https://citeline.com/solutions/competitive-intelligence/
  why: Offers drug pipeline intelligence and competitive monitoring for the same biopharma decision makers.
• name: Evaluate
  why: Provides pharma market intelligence and forecasting used in related asset and portfolio decisions.
• name: Cortellis
  why: Competitive intelligence offering for pharmaceutical development and market research.

influencers

• name: Arjun Murthy
  url: https://som.yale.edu/story/2024/startup-stories-accelerating-search-new-medicines
  why: Co-founder discussing the problem of accelerating pharmaceutical research.

keywords

• biopharma competitive intelligence
• drug pipeline monitoring
• clinical trial landscape analysis
• biotech asset screening
• pharma market access intelligence
• biopharma AI research
• pharma diligence software

voice

• Analytical and evidence-led
• Decision-focused
• Measured and professional

signals

• text: A portfolio team is entering a therapeutic area or refreshing a competitive landscape.
• text: A consultant or investor maintains recurring diligence files that must respond to clinical or regulatory developments.

stack

• Claude
• MCP
• API
• webhooks
• Microsoft Word
• Excel
• PowerPoint

hiring

• Software Engineer, Full Stack

pricing

motion

channels

• LinkedIn
• SEO
• founder-led sales

confidence

Founders

• name: Michael Brady
  title: Founder
  role: Founder
  bio: Helping BioPharma teams evaluate therapeutic opportunities. Passionate about building AI-native software. Boston native.
• name: Arjun Murthy
  title: Founder
  role: Founder
  bio: Proactive Biopharma intelligence. Passionate about helping teams in life sciences navigate complexity with the right information at the right time.